We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 07, 2020

Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries
JAMA Oncol 2019 Dec 19;[EPub Ahead of Print], ST Bird, F Tian, N Flowers, D Przepiorka, R Wang, TH Jung, Z Kessler, C Woods, B Kim, BW Miller, M Wernecke, C Kim, S McKean, K Gelperin, TE MaCurdy, JA Kelman, DJ Graham

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading